CDK6 and cancer: The interaction of CDK4 and CDK6 with D-type cyclins constitutively phosphorylates and inactivates the retinoblastoma protein (Rb), a tumor suppressor, causing the release of its binding partner, E2 transcription factor (E2F), allowing cancer cells to overcome pRb-dependent growth suppression [18].